Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2809-13.

    An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

    Source

    University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA.

    Erratum in

    • Proc Natl Acad Sci U S A 2000 May 9;97(10):5679.

    Abstract

    Decreased elasticity of the cardiovascular system is one of the hallmarks of the normal aging process of mammals. A potential explanation for this decreased elasticity is that glucose can react nonenzymatically with long-lived proteins, such as collagen and lens crystallin, and link them together, producing advanced glycation endproducts (AGEs). Previous studies have shown that aminoguanidine, an AGE inhibitor, can prevent glucose cross-linking of proteins and the loss of elasticity associated with aging and diabetes. Recently, an AGE cross-link breaker (ALT-711) has been described, which we have evaluated in aged dogs. After 1 month of administration of ALT-711, a significant reduction ( approximately 40%) in age-related left ventricular stiffness was observed [(57.1 +/- 6.8 mmHg x m(2)/ml pretreatment and 33.1 +/- 4.6 mmHg x m(2)/ml posttreatment (1 mmHg = 133 Pa)]. This decrease was accompanied by improvement in cardiac function.

    PMID:
    10706607
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC16011
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk